Japan’s Shionogi To Buy Sciele Of U.S. For $1.4 Billion
This article was originally published in PharmAsia News
Executive Summary
Shionogi of Japan plans to pay $1.4 billion to acquire the U.S. firm Sciele Pharma in a foreign expansion move. The company becomes the latest in a string of Japanese pharmaceutical companies to buy firms abroad as Japan moves to reduce the prices of drugs for its citizens. Based partly on its best-seller drug Crestor (rosuvastatin) for lowering cholesterol, 82 percent of Shionogi's sales currently come from Japan. The purchase would expand the Japanese company's research and development stafff and provide it with its own U.S. sales staff. Shionogi suffered its slowest growth in profit in the first half of this year even though sales increased by 3 percent. (Click here for more
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.